Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy

Solventum (NYSE: SOLV) has received FDA 510(k) clearance for the combined use of its Restrata Synthetic Electrospun Fiber Matrix and V.A.C. Therapy. This regulatory approval follows Solventum's acquisition of Acera Surgical in December 2025, enabling the integration of two advanced wound healing technologies to enhance active wound healing.